Literature DB >> 36057012

Semiquantitative analysis using whole-body dynamic F-18 fluoro-2-deoxy-glucose-positron emission tomography to differentiate between benign and malignant lesions.

Mirei Watanabe1, Hiroki Kato2,3, Daisuke Katayama1, Fumihiko Soeda1, Keiko Matsunaga4, Tadashi Watabe1, Mitsuaki Tatsumi1,5, Eku Shimosegawa4, Noriyuki Tomiyama5.   

Abstract

OBJECTIVES: To investigate whether whole-body dynamic positron emission tomography (PET) is useful for differentiating benign and malignant lesions.
METHODS: In this retrospective study, data from a cohort of 146 lesions from 187 patients who consecutively underwent whole-body dynamic PET scans at our hospital for suspected lesions in the lung, lymph nodes, liver, bone, esophagus, and colon were analyzed. Patients with malignant lymphomas, accumulations > 5 cm in length along the long axis of the esophagus, or lesions in the colon in which the site of accumulation moved during the imaging period were excluded. Patients were administered 3.7 MBq/kg of fluorine-18-fluorodeoxyglucose (F-18 FDG), and dynamic imaging was initiated 60 min after administration. We defined the 60-65, 65-70, 70-75, and 75-80 min time mark as the first, second, third, and fourth pass, respectively. The static image is the summed average of all the four pass images. We measured the accumulation in the mean image of the whole-body dynamic PET scan, which was arithmetically similar to the maximum standardized uptake value (SUVmax) throughout the whole-body static images obtained during 20 min of imaging (S-SUVmax). The ratio of SUVmax in the dynamic first pass(60-65 min after FDG administration) and fourth pass(75-80 min after FDG administration) was calculated as R-SUVmax.
RESULTS: The S-SUVmax in the lung, lymph nodes, and bone did not differ significantly between the benign and malignant groups. However, there was a significant difference in R-SUVmax, which was > 1 in most malignant lesions indicating an increase in accumulation during routine scan time. Significant differences were observed between benign and malignant lesions of the liver in both S-SUVmax and R-SUVmax values, with the latter being > 1 in most malignant lesions.
CONCLUSIONS: Whole-body dynamic PET for 20 min starting 1 h after FDG administration improved the accuracy of malignant lesion detection in the liver, lymph nodes, lung, and bone. The incremental improvement was small, and the FDG dynamics in the distribution of values between benign and malignant overlapped. Additional information from whole-body dynamic imaging can help detect malignant lesions in these sites without increasing patient burden or prolonging imaging time.
© 2022. The Author(s) under exclusive licence to The Japanese Society of Nuclear Medicine.

Entities:  

Keywords:  Diagnosis; Malignant lesion; Whole-body dynamic PET

Year:  2022        PMID: 36057012     DOI: 10.1007/s12149-022-01784-y

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN: 0914-7187            Impact factor:   2.258


  6 in total

1.  Does dual-time-point 18F-FDG PET/CT scan add in the diagnosis of hepatocellular carcinoma?

Authors:  Bing Wu; Yanzhao Zhao; Yiqiu Zhang; Hui Tan; Hongcheng Shi
Journal:  Hell J Nucl Med       Date:  2017-03-20       Impact factor: 1.102

2.  Fluorine-18-fluorodeoxyglucose assessment of glucose metabolism in bone tumors.

Authors:  A C Kole; O E Nieweg; H J Hoekstra; J R van Horn; H S Koops; W Vaalburg
Journal:  J Nucl Med       Date:  1998-05       Impact factor: 10.057

3.  Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes.

Authors:  H Zhuang; M Pourdehnad; E S Lambright; A J Yamamoto; M Lanuti; P Li; P D Mozley; M D Rossman; S M Albelda; A Alavi
Journal:  J Nucl Med       Date:  2001-09       Impact factor: 10.057

4.  18F-FDG PET for the diagnosis and grading of soft-tissue sarcoma: a meta-analysis.

Authors:  John P A Ioannidis; Joseph Lau
Journal:  J Nucl Med       Date:  2003-05       Impact factor: 10.057

5.  Evaluation of liver tumors using fluorine-18-fluorodeoxyglucose PET: characterization of tumor and assessment of effect of treatment.

Authors:  S Okazumi; K Isono; K Enomoto; T Kikuchi; M Ozaki; H Yamamoto; H Hayashi; T Asano; M Ryu
Journal:  J Nucl Med       Date:  1992-03       Impact factor: 10.057

6.  High accumulation of fluorine-18-fluorodeoxyglucose in turpentine-induced inflammatory tissue.

Authors:  S Yamada; K Kubota; R Kubota; T Ido; N Tamahashi
Journal:  J Nucl Med       Date:  1995-07       Impact factor: 10.057

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.